4.2 Article

Screening for serious mental illness in the general population with the K6 screening scale: results from the WHO World Mental Health (WMH) survey initiative

出版社

WILEY
DOI: 10.1002/mpr.310

关键词

K6 screening scale; psychiatric epidemiology; serious mental illness (SMI)

资金

  1. Bristol-Myers Squibb
  2. Eli Lilly & Company Foundation
  3. GlaxoSmithKline
  4. Johnson & Johnson Pharmaceuticals
  5. Ortho-McNeil Pharmaceuticals Inc.
  6. Pfizer Inc.
  7. Sanofi-Aventis
  8. United States National Institute of Mental Health [R01MH070884]
  9. John D. and Catherine T. MacArthur Foundation
  10. Pfizer Foundation
  11. US Public Health Service [R13-MH066849, R01-MH069864, R01 DA016558]
  12. Fogarty International Center (FIRCA) [R03-TW006481]
  13. Pan American Health Organization
  14. Shire
  15. State of Sao Paulo Research Foundation (FAPESP) [03/00204-3]
  16. Ministry of Health and the National Center for Public Health Protection
  17. Shenzhen Bureau of Health
  18. Shenzhen Bureau of Science, Technology, and Information
  19. Ministry of Social Protection
  20. WHO (India)
  21. Japan Ministry of Health, Labour, and Welfare [H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013]
  22. Lebanese Ministry of Public Health
  23. WHO (Lebanon), Fogarty International, Act for Lebanon
  24. Janssen Cilag
  25. Roche
  26. Novartis
  27. The National Institute of Psychiatry Ramon de la Fuente (INPRFMDIES) [4280]
  28. National Council on Science and Technology [CONACyT-G30544-H]
  29. Pan American Health Organization (PAHO)
  30. New Zealand Ministry of Health, Alcohol Advisory Council
  31. Health Research Council
  32. WHO (Geneva)
  33. WHO (Nigeria)
  34. Federal Ministry of Health, Abuja, Nigeria
  35. Ministry of Public Health
  36. Eli Lilly Romania SRL
  37. US National Institute of Mental Health [R01-MH059575, RO1-MH61905, U01-MH60220]
  38. South African Department of Health
  39. University of Michigan
  40. National Institute of Drug Abuse (NIDA)
  41. Substance Abuse and Mental Health Services Administration (SAMHSA)
  42. Robert Wood Johnson Foundation (RWJF) [044708]
  43. John W. Alden Trust
  44. Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [03/00204-3] Funding Source: FAPESP

向作者/读者索取更多资源

Data are reported on the background and performance of the K6 screening scale for serious mental illness (SMI) in the World Health Organization (WHO) World Mental Health (WMH) surveys. The K6 is a six-item scale developed to provide a brief valid screen for Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV) SMI based on the criteria in the US ADAMHA Reorganization Act. Although methodological studies have documented good K6 validity in a number of countries, optimal scoring rules have never been proposed. Such rules are presented here based on analysis of K6 data in nationally or regionally representative WMH surveys in 14 countries (combined N = 41,770 respondents). Twelve-month prevalence of DSM-IV SMI was assessed with the fully-structured WHO Composite International Diagnostic Interview. Nested logistic regression analysis was used to generate estimates of the predicted probability of SMI for each respondent from K6 scores, taking into consideration the possibility of variable concordance as a function of respondent age, gender, education, and country. Concordance, assessed by calculating the area under the receiver operating characteristic curve, was generally substantial (median 0.83; range 0.76-0.89; inter-quartile range 0.81-0.85). Based on this result, optimal scaling rules are presented for use by investigators working with the K6 scale in the countries studied. Copyright (c) 2010 John Wiley & Sons, Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据